Abstract
Recent advances in genetic diagnosis identified variants in genes encoding GABAA receptors as causative for genetic epilepsy. Here, we selected eight disease-associated variants in the α1 subunit of GABAA receptors causing mild to severe clinical phenotypes and showed that they are loss of function, mainly by reducing the folding and surface trafficking of the α1 protein. Furthermore, we sought client protein-specific pharmacological chaperones to restore the function of pathogenic receptors. Applications of positive allosteric modulators, including Hispidulin and TP003, increase the functional surface expression of the α1 variants. Mechanism of action study demonstrated that they enhance the folding, assembly, and trafficking and reduce the degradation of GABAA variants without activating the unfolded protein response in HEK293T cells and human iPSC-derived neurons. Since these compounds cross the blood-brain barrier, such a pharmacological chaperoning strategy holds great promise to treat genetic epilepsy in a GABAA receptor-specific manner.
Keywords:
Bretazenil (PubChem CID: 107926); CGS20625 (PubChem CID: 163844); CL218872 (PubChem CID: 107950); Chlormezanone (PubChem CID: 2717); Epilepsy; Florazepam (PubChem CID: 3393); GABA (PubChem CID: 119); GABA(A) receptors; Hispidulin (PubChem CID: 5281628); Midazolam (PubChem CID: 4192); Pharmacological chaperones; Proteostasis; TP003 (PubChem CID: 10001434); ZK93423 (PubChem CID: 56972166); iPSC.